BioArctic AB (BIOA B.ST) stock: key figures, P/E, revenue and dividend
Health Care · Sweden · ISIN SE0010323311
BioArctic AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 257.00 m SEK | 2.00 bn SEK |
| Gross profit | 230.00 m SEK | 1.94 bn SEK |
| Operating income | -229.62 m SEK | 1.37 bn SEK |
| EBIT | -222.00 m SEK | 1.26 bn SEK |
| Net income | -177.00 m SEK | 1.02 bn SEK |
| Diluted EPS – continuing operations | -2.00 SEK | 11.52 SEK |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BioArctic AB
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment. Further, it is developing lecanemab for subcutaneous treatment; lecanemab, which is in Phase 3 clinical trials for presymptomatic treatment; exidavnemab, which is in Phase 2 clinical trials; lecanemab back-up, BAN2803, ND3014, and BAN2802, which are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, and PD-BT2238, which are in the research stage. The company has a research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule, and with Mesenkia Therapeutics to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
More stocks
- Asker Healthcare Group AB (ASKER.ST)
- Peab AB (PEAB B.ST)
- Shenzhen Honor Electronic Co Ltd (300870.SZ)
- Primarius Technologies Co. Ltd. A (688206.SS)
- FIRST BANCORP /NC/ (FBNC)
- Salzgitter (SZG.DE)
- Beijing Venustech Inc (002439.SZ)
- China Science Publishing & Media Ltd (601858.SS)
- Chongqing Brewery Co Ltd (600132.SS)
- Shake Shack Inc. (SHAK)
- MLOptic Corp. A (688502.SS)
- F&G Annuities & Life, Inc. (FG)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.